295 Results
Sort By:
Published on April 20, 2022
Research led by the University of Michigan shows that it is possible to detect early to late-stage melanoma skin cancer through a blood test that detects circulating tumor cells in the blood. As well as showing potential for cancer detection, the researchers showed the test can also be used to…
Published on April 15, 2022
Harvard Medical School (HMS) Researchers have developed spatial maps of melanoma that show how individual cells interact as the cancer progresses. The maps reveal details of how melanoma suppresses the immune system as it takes over. The findings are published in the journal Cancer Discovery. When caught early, melanoma can often…
Published on March 30, 2022
The U.S. Food and Drug Administration has approved the use of the anti-lymphocyte-activation gene (LAG)-3 agent relatlimab in combination with the anti-programmed death (PD)-1 drug nivolumab for patients with treatment-naïve advanced melanoma. The approval is based on the results of the Phase II/III RELATIVITY-047 trial published in the New England…
Published on March 14, 2022
A new study reveals key differences in the cellular and molecular composition of acral melanoma compared with melanoma, according to Moffitt Cancer Center & Research Institute researchers, which may lead to new potential therapeutic targets for the rare skin cancer. Their findings are published in the journal Clinical Cancer Research…
Published on February 17, 2022
Researchers at Wake Forest School of Medicine report that they have found biomarkers that indicate whether a patient will benefit from the use of immune checkpoint inhibitors (ICIs) to treat melanoma. Melanoma is often curable if discovered and treated in its earliest stages, but when the disease progresses it can…
Published on January 26, 2022
Commercial stage biotech drug developer Immunocore Holdings announced on Wednesday that the FDA has granted marketing approval for KIMMTRAK (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), making it the only FDA-approved treatment specifically targeting the disease. The drug also becomes the first…
Published on January 19, 2022
A pioneering test that reliably predicts the spread or return of melanoma has been developed by a team of Newcastle University scientists and clinicians. The research describing the test’s biological underpinnings was published Nov. 13 in the British Journal of Dermatology. In this study, the researchers detail how early-stage melanomas at…
Published on December 27, 2021
New research headed by teams at the University of Texas MD Anderson Cancer Center and the Center for Cancer Research at the National Cancer Institute (NCI) suggest that a high-fiber diet may help some melanoma patients respond better to immunotherapy treatments by influencing the gut microbiome. The study found that…
Published on December 21, 2021
Researchers have described mechanisms involved in focal amplification (FA) of BRAF and other genes in the MAPK signaling pathway, which is a driver of many cancer types. These findings could help further understanding of drug resistance to particular drugs for cancers, including melanoma. “This study was designed to provide details…
Published on July 15, 2021
An unmet need remains for novel immune checkpoint inhibitor combinations that achieve durable and deep responses in patients with metastatic melanoma, without adding substantial toxicity. Results from the Phase II PIVOT-02 study in untreated metastatic melanoma has shown the combination of interleukin-2 (IL-2) pathway agonist bempegaldesleukin (BEMPEG) plus the immunotherapy nivolumab…
Published on July 12, 2021
Specific intestinal microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. The researchers also identified a potential new strategy to treat toxicity, while maintaining response to combined…
Published on May 19, 2021
Researchers at the Salk Institute have uncovered a “genetic switch,” involving CRTC3, that seems to play a key role in the development of melanoma, and which could be a new target for drug developers. BRAF inhibitors are sometimes effectives against melanoma, but relapse and treatment resistance rates are high. This…
Published on February 5, 2021
Scientists from the NIH in collaboration with UPMC Hillman Cancer Center, reporting in Science, have demonstrated in a Phase II proof-of-principal study how some patients with advanced melanoma who haven’t responded to immune checkpoint inhibitor therapy, can be converted to immunotherapy responders by giving them a fecal microbiota transplant (FMT),…
Published on January 21, 2021
In encouraging news regarding melanoma therapy, researchers found that a personalized vaccine continues to keep cancer cells in check four years after patients received it. In a Phase 1 study among eight patients with advanced melanoma who received the NeoVax vaccine, after a median of four years, all of the…
Published on November 18, 2020
An AI neural network can accurately predict the prognosis of melanoma patients based on pre-treatment histology imaging data, shows research led by the NYU Grossman School of Medicine. Immune checkpoint inhibitors have revolutionized melanoma treatment, but only some tumors respond well to them and they can be quite toxic to…